Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Findings of 4 years follow-up from the CheckMate 142 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Long-Term Survival in a Significant Proportion of Patients with a 1p/19q Codeleted Anaplastic Oligodendroglioma
Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy
EMA Recommends Extension of Therapeutic Indications for Olaparib
New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer
Age and Frailty Should Be Considered Independently When Evaluating Potential Risk for Side Effects Among Older Adults Treated with ICIs
Findings from a population-level retrospective cohort study
FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the ELARA study
EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients
The risk of ocular toxicity, including risk of severe visual loss and need for monitoring in paediatric patients treated with crizotinib
An Updated Overview of Estimates for Cancer Incidence and Mortality in the Latin America and the Caribbean Region
Data for 32 countries in this region reflect important underlying sociodemographic changes
Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade Squamous Intraepithelial Lesions
Findings from a phase III ANCHOR study
Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT for Perioperative Treatment of Resectable, HER2-positive Oesophagogastric Adenocarcinoma
Improved pathologic complete response and nodal negativity rates, but higher rates of diarrhoea and leukopenia observed
A Clinical Signal of Efficacy Observed with a Combination of Nivolumab and Ipilimumab Over Platinum Doublet in Fit Elderly Patients with Advanced NSCLC
Findings from the Energy-GFPC 06-2015 study
Carriers of a Germline Pathogenic Variant in CDKN2A are at a High Lifetime Risk of Pancreatic Ductal Adenocarcinoma
Surveillance in this population leads to diagnosis of early-stage disease in one third of patients resulting in increased resectability and a substantial 5-year survival rate
EMA Recommends Extension of Therapeutic Indications for Selinexor
New indication concerns a combination of selinexor with bortezomib and dexamethasone for the treatment of multiple myeloma